Published in J Intern Med on January 01, 2010
Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett (2014) 1.37
Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther (2012) 1.19
Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol Rev (2012) 1.15
Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev (2013) 1.12
Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano (2012) 1.08
Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One (2012) 1.06
Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS Nano (2011) 1.06
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res (2012) 1.05
Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01
Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol (2011) 0.98
Will nanotechnology influence targeted cancer therapy? Semin Radiat Oncol (2011) 0.95
Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Mol Ther (2013) 0.93
Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Mol Ther Nucleic Acids (2013) 0.93
Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int (2013) 0.92
Effect of magnetic fields on tumor growth and viability. Comp Med (2011) 0.91
MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression. Nat Commun (2016) 0.90
Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.90
Coordinated targeting of the EGFR signaling axis by microRNA-27a*. Oncotarget (2013) 0.89
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev (2015) 0.89
An influenza virus-inspired polymer system for the timed release of siRNA. Nat Commun (2013) 0.88
Non-coding RNAs as theranostics in human cancers. J Cell Biochem (2012) 0.85
Nanotechnology and the treatment of HIV infection. Viruses (2012) 0.84
Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomedicine (2012) 0.83
Controllable labelling of stem cells with a novel superparamagnetic iron oxide-loaded cationic nanovesicle for MR imaging. Eur Radiol (2012) 0.81
Lipid-based vectors for siRNA delivery. J Drug Target (2012) 0.81
Formulation Strategies, Characterization, and In Vitro Evaluation of Lecithin-Based Nanoparticles for siRNA Delivery. J Drug Deliv (2012) 0.80
Transarterial chemoembolization of hepatocellular carcinoma in a rat model: the effect of additional injection of survivin siRNA to the treatment protocol. BMC Cancer (2016) 0.79
RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J (2016) 0.78
Porous silicon microparticles for delivery of siRNA therapeutics. J Vis Exp (2015) 0.78
Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study. Am J Obstet Gynecol (2015) 0.77
Novel lipoidal amine-based nanocarrier formulations for siRNA delivery. Ther Deliv (2012) 0.76
Lipid Nanoparticle-mediated siRNA Transfer Against PCTAIRE1/PCTK1/Cdk16 Inhibits In Vivo Cancer Growth. Mol Ther Nucleic Acids (2016) 0.76
Mono-arginine Cholesterol-based Small Lipid Nanoparticles as a Systemic siRNA Delivery Platform for Effective Cancer Therapy. Theranostics (2016) 0.76
Development of dual-activity vectors by co-envelopment of adenovirus and SiRNA in artificial lipid bilayers. PLoS One (2014) 0.75
Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis. Nanomaterials (Basel) (2016) 0.75
Self-assembly of c-myc DNA promoted by a single enantiomer ruthenium complex as a potential nuclear targeting gene carrier. Sci Rep (2016) 0.75
Evaluation of antitumor activity of survivin short interfering RNA delivered by lipid nanoparticles in colon cancer in vitro and in vivo. Oncol Lett (2017) 0.75
Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer. Proc Natl Acad Sci U S A (1981) 6.03
Monitoring dopants by Raman scattering in an electrochemically top-gated graphene transistor. Nat Nanotechnol (2008) 5.08
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 3.86
Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis (1985) 2.64
Graphene: the new two-dimensional nanomaterial. Angew Chem Int Ed Engl (2009) 2.53
Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst (1999) 2.49
Carbon nanotube flow sensors. Science (2003) 2.23
Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta (1984) 2.21
A rapid and convenient synthesis of poly-thymidylic acid by the modified triester approach. Nucleic Acids Res (1977) 2.15
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol (1987) 1.83
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer (2007) 1.78
Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv (1984) 1.74
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis (1984) 1.67
In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother (1984) 1.58
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis (1990) 1.46
Chemical synthesis of versatile adaptors for molecular cloning. Biochem Biophys Res Commun (1978) 1.45
Recurrent carcinoma in situ of a neovagina. Gynecol Oncol (2001) 1.43
Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv (1983) 1.43
Recurrent bacterial meningitis. J Assoc Physicians India (1994) 1.41
Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood (1994) 1.41
Probing 2D black phosphorus by quantum capacitance measurements. Nanotechnology (2015) 1.40
Nutritional beliefs amongst Anganwadi workers. Indian Pediatr (1992) 1.38
Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother (1987) 1.38
Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res (2001) 1.33
Sequences of human repetitive DNA, non-alpha-globin genes, and major histocompatibility locus genes. Cold Spring Harb Symp Quant Biol (1983) 1.33
Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother (1993) 1.32
Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis (1992) 1.30
Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother (1987) 1.28
Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother (1987) 1.26
Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging (2000) 1.24
Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukoc Biol (1994) 1.24
Molecular organization of the class I genes of human major histocompatibility complex. Immunol Rev (1985) 1.24
Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res (1984) 1.23
Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother (1986) 1.22
Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother (1994) 1.20
The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer (2000) 1.20
Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother (1994) 1.19
Preservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva. Cancer (2000) 1.19
Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med (1991) 1.17
Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother (1997) 1.16
Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B. Antimicrob Agents Chemother (1984) 1.15
Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci (1994) 1.15
Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. Cancer (2000) 1.14
Structure and polymorphism of class I MHC antigen mRNA. Immunogenetics (1985) 1.14
Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect Immun (1985) 1.12
Cusp-level chordal shortening for rheumatic mitral regurgitation: early results. Tex Heart Inst J (1992) 1.11
Use of synthetic oligonucleotide probes complementary to genes for human HLA-DR alpha and beta as extension primers for the isolation of 5'-specific genomic clones. Proc Natl Acad Sci U S A (1983) 1.09
Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope (1987) 1.09
Inhibition of HIV replication by liposomal encapsulated amphotericin B. Antiviral Res (1989) 1.01
Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene (2008) 1.01
Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene (1999) 1.01
Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother (1997) 1.00
Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann N Y Acad Sci (1985) 1.00
Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant (1992) 1.00
Expression of tissue transglutaminase in cultured monocytic leukemia (THP-1) cells during differentiation. Cancer Res (1986) 0.99
Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res (2001) 0.99
Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer (1986) 0.98
Confined glassy dynamics at grain boundaries in colloidal crystals. Proc Natl Acad Sci U S A (2011) 0.98
Mitral valve reconstruction: early results of a modified cooley technique. Tex Heart Inst J (1992) 0.98
Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene (1997) 0.97
Assessment of knowledge and skills about growth monitoring amongst medical officers, child development project officers and multi purpose workers. Indian Pediatr (1994) 0.97
Comparison of different criteria for measurement of obesity in a community. Indian J Med Res (1984) 0.97
Sharp Raman anomalies and broken adiabaticity at a pressure induced transition from band to topological insulator in Sb2Se3. Phys Rev Lett (2013) 0.97
Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur J Clin Microbiol Infect Dis (1997) 0.96
Epidemiological study of hypertension in young (15-24 yr) Delhi urban population. Indian J Med Res (1994) 0.96
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood (1999) 0.95
Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites. Immunology (1984) 0.95
GRB2: a pivotal protein in signal transduction. Semin Oncol (2001) 0.94
Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther (2006) 0.92
Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology (1986) 0.92
Hematogenous skin metastases from cervical cancer at primary presentation. Gynecol Oncol (2000) 0.92
The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch Med Res (1993) 0.92
Observation of chaotic dynamics in dilute sheared aqueous solutions of CTAT. Phys Rev Lett (2000) 0.92
Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives. Cancer Immunol Immunother (1986) 0.92
Thermodynamics of water entry in hydrophobic channels of carbon nanotubes. J Chem Phys (2011) 0.91
Activated macrophages secrete a soluble factor that inhibits mitochondrial respiration of tumor cells. J Immunol (1984) 0.91
Effect of silica colloids on the rheology of viscoelastic gels formed by the surfactant cetyl trimethylammonium tosylate. J Colloid Interface Sci (2005) 0.90
Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leuk Res (1994) 0.90
Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res (1993) 0.89
Induction of adenosine deaminase and 5' nucleotidase activity in cultured human blood monocytes and monocytic leukemia (THP-1) cells by differentiating agents. J Leukoc Biol (1988) 0.89
Combination of single walled carbon nanotubes/graphene oxide with paclitaxel: a reactive oxygen species mediated synergism for treatment of lung cancer. Nanoscale (2013) 0.89
Depression in pregnancy and postpartum period. Indian J Psychiatry (2003) 0.88
Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis (1996) 0.88
Toxicity of exposed aluminium phosphide. J Assoc Physicians India (1993) 0.88
Graphene oxide-MnFe2O4 magnetic nanohybrids for efficient removal of lead and arsenic from water. ACS Appl Mater Interfaces (2014) 0.88
Liposomes in infectious diseases: present and future. Curr Clin Top Infect Dis (1989) 0.87
The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol (1983) 0.87
Liposomal amphotericin B in the treatment of fungal infections. Ann Intern Med (1986) 0.87
Design, fabrication, and characterization of a tissue-equivalent phantom for optical elastography. J Biomed Opt (2005) 0.87
Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene (2000) 0.87
Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J Pharmacol Exp Ther (1999) 0.87
Signaling mechanisms mediating muscarinic enhancement of GABAergic synaptic transmission in the spinal cord. Neuroscience (2008) 0.86
Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo. J Infect Dis (1991) 0.86
Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ (1997) 0.86
Assessment of knowledge and skills about growth monitoring amongst multipurpose workers in an ICDS project. Indian Pediatr (1991) 0.86
Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticuloendothel Soc (1982) 0.86
Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood (1996) 0.85